TAB3 (TAK1-Binding Protein 3) is an essential adaptor protein in the NF-κB and MAPK signaling pathways. TAB3 partners with TAB2 to mediate the activation of TAK1 (MAP3K7) downstream of pro-inflammatory cytokines, toll-like receptors (TLRs), and growth factor receptors. Given the central role of chronic neuroinflammation in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), TAB3 has emerged as a critical regulator of neuroinflammatory processes and a potential therapeutic target.
| TAK1-Binding Protein 3 | |
|---|---|
| Gene Symbol | TAB3 |
| Full Name | TAK1 Binding Protein 3 |
| Chromosomal Location | Xp11.23 |
| NCBI Gene ID | [85413](https://www.ncbi.nlm.nih.gov/gene/85413) |
| OMIM | 300501 |
| Ensembl ID | ENSG00000169340 |
| UniProt ID | [Q9P0G2](https://www.uniprot.org/uniprot/Q9P0G2) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Neuroinflammation |
TAB3 encodes TAK1-binding protein 3, an essential adaptor protein in the NF-κB and MAPK signaling pathways. TAB3 partners with TAB2 to mediate the activation of TAK1 (MAP3K7) downstream of TLRs, IL-1R, TNF receptors, and TGF-β receptors. Upon receptor activation, TAB3/TAB2 recruits TAK1 to the signaling complex, leading to TAK1 autophosphorylation and activation of downstream NF-κB and JNK pathways. TAB3 is critical for innate immune responses, inflammatory cytokine production, cell survival, and stress responses.
| TAK1-Binding Protein 3 | |
|---|---|
| Gene Symbol | TAB3 |
| Full Name | TAK1 Binding Protein 3 |
| Chromosome | Xp11.23 |
| NCBI Gene ID | [85413](https://www.ncbi.nlm.nih.gov/gene/85413) |
| OMIM | 300501 |
| Ensembl ID | ENSG00000169340 |
| UniProt ID | [Q9P0G2](https://www.uniprot.org/uniprot/Q9P0G2) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Inflammation |
TAB3 encodes TAK1-binding protein 3, an essential adaptor protein in the NF-κB and MAPK signaling pathways. TAB3 partners with TAB2 to mediate the activation of TAK1 (MAP3K7) downstream of TLRs, IL-1R, TNF receptors, and TGF-β receptors. Upon receptor activation, TAB3/TAB2 recruits TAK1 to the signaling complex, leading to TAK1 autophosphorylation and activation of downstream NF-κB and JNK pathways. TAB3 is critical for innate immune responses, inflammatory cytokine production, cell survival, and stress responses.
TAB3 contains several key structural domains:
The ubiquitin-binding function of TAB3 is critical — Lys63-linked ubiquitin chains on receptor-interacting proteins (e.g., RIP1, TRAF6) serve as platforms to recruit the TAB2/TAB3/TAK1 complex, enabling signal transduction.
TAB3 mediates signaling downstream of multiple receptor families:[1]
TAB3 is widely expressed across multiple tissue types:
In the central nervous system, TAB3 is expressed in:[2]
Expression is upregulated in response to:[3]
TAK1 activation downstream of TAB3 triggers:[4]
TAK1/TAB3 signaling is a major driver of neuroinflammation:[5]
TAK1/TAB3 signaling contributes to AD pathogenesis through multiple mechanisms:[6]
Research has shown that:[7]
TAK1/TAB3 signaling is implicated in PD pathogenesis:[8]
TAK1 contributes to ALS progression:[9]
Several TAK1 inhibitors have been explored for neurodegenerative diseases:[14]
| Compound | Mechanism | Stage | Reference |
|---|---|---|---|
| (5Z)-7-Oxozeaenol | Irreversible TAK1 inhibition | Preclinical | -- |
| LL-Z1640-2 | Reversible TAK1 inhibition | Preclinical | -- |
| NG25 | TAK1/NIK inhibitor | Preclinical | -- |
TAB3 interacts with:
Tab3 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Tab3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Mumby M, et al. TAB proteins regulate the activation of MAPKKs and downstream pathways. 2004. ↩︎
Bjorklund M, et al. TAK1 mediates inflammatory response in glial cells. 2006. ↩︎
Gera N, et al. TAK1/TAB signaling in neuroinflammation. 2019. ↩︎
Inohara N, et al. Dissecting the role of TAB2 and TAB3 in NF-kappaB activation. 2005. ↩︎
Bhardwaj G, et al. TAK1 activation in neurodegeneration. 2015. ↩︎
Yang Y, et al. TAK1 in Alzheimer's disease. 2017. ↩︎
Hu B, et al. TAK1 mediates Abeta-induced neuroinflammation. 2018. ↩︎
Song J, et al. TAK1 inhibition protects against MPTP-induced Parkinsonism. 2016. ↩︎
Chen Y, et al. ALS-linked SOD1 mutation affects TAK1 signaling. 2014. ↩︎
Liu J, et al. TAK1 promotes motor neuron degeneration in ALS. 2016. ↩︎
Xu J, et al. TAK1/TAB1 in traumatic brain injury. 2018. ↩︎
Wu J, et al. TAK1 deficiency protects against ischemic stroke. 2019. ↩︎
Zhang L, et al. Down syndrome and TAK1 signaling. 2018. ↩︎
Yuan Z, et al. TAK1 inhibitors for neurodegenerative diseases. 2019. ↩︎